Wave Life Sciences (HAM:0VS) Cyclically Adjusted Book per Share: €2.32 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:0VS Wave Life Sciences Inc HAM:0VS
58 GF Score
Price €4.96
GF Value €3.90
! 4 Warning Signs
View Full Analysis

What is Wave Life Sciences Cyclically Adjusted Book per Share?

Wave Life Sciences HAM:0VS 58 Cyclically Adjusted Book per Share is €2.32 as of Jun. 2026. GuruFocus rates HAM:0VS with a GF Score™ of 58/100 and a GF Value™ of €3.90. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Wave Life Sciences's adjusted book value per share for the three months ended in Jun. 2026 was €2.037. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.32 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Wave Life Sciences's average Cyclically Adjusted Book Growth Rate was -12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-14), Wave Life Sciences's current stock price is €4.96. Wave Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €2.32. Wave Life Sciences's Cyclically Adjusted PB Ratio of today is 2.14.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Wave Life Sciences was 5.61. The lowest was 1.53. And the median was 2.43.


Wave Life Sciences  (HAM:0VS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Wave Life Sciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=4.96/2.32
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Wave Life Sciences was 5.61. The lowest was 1.53. And the median was 2.43.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Wave Life Sciences Cyclically Adjusted Book per Share Related Terms


Wave Life Sciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Wave Life Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wave Life Sciences Cyclically Adjusted Book per Share Chart

Wave Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Wave Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 2.40 2.32

HAM:0VS vs FBRX, SVRA, SPTX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Wave Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wave Life Sciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wave Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Wave Life Sciences's Cyclically Adjusted PB Ratio falls into.


HAM:0VS
58GF Score
Wave Life Sciences Inc HAM:0VS
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wave Life Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Wave Life Sciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.037/333.9520*333.9520
=2.037

Current CPI (Jun. 2026) = 333.9520.

Wave Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 5.737 241.428 7.936
201612 5.440 241.432 7.525
201703 4.648 243.801 6.367
201706 6.063 244.955 8.266
201709 5.011 246.819 6.780
201712 4.239 246.524 5.742
201803 3.188 249.554 4.266
201806 4.070 251.989 5.394
201809 3.105 252.439 4.108
201812 2.188 251.233 2.908
201903 5.086 254.202 6.682
201906 4.138 256.143 5.395
201909 3.040 256.759 3.954
201912 1.670 256.974 2.170
202003 0.546 258.115 0.706
202006 -0.112 257.797 -0.145
202009 1.884 260.280 2.417
202012 1.395 260.474 1.789
202103 0.890 264.877 1.122
202106 0.358 271.696 0.440
202109 0.489 274.310 0.595
202112 0.481 278.802 0.576
202203 -0.001 287.504 -0.001
202206 0.338 296.311 0.381
202209 -0.053 296.808 -0.060
202212 -0.490 296.797 -0.551
202303 -0.330 301.836 -0.365
202306 -0.484 305.109 -0.530
202309 -0.383 307.789 -0.416
202312 0.305 306.746 0.332
202403 0.191 312.332 0.204
202406 -0.026 314.175 -0.028
202409 0.860 315.301 0.911
202412 1.307 315.605 1.383
202503 1.031 319.799 1.077
202506 0.776 322.561 0.803
202509 0.662 324.800 0.681
202512 2.359 324.054 2.431
202603 2.301 330.213 2.327
202606 2.037 333.952 2.037

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €2.32 mean?
Wave Life Sciences (HAM:0VS) has a Cyclically Adjusted Book per Share of €2.32 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Wave Life Sciences and its competitors.
Is Wave Life Sciences' Cyclically Adjusted Book per Share too high?
Wave Life Sciences' current Cyclically Adjusted Book per Share is €2.32. Overall, Wave Life Sciences has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' Cyclically Adjusted Book per Share compare to FBRX and SVRA?
Wave Life Sciences' Cyclically Adjusted Book per Share of €2.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Wave Life Sciences and its competitors. Wave Life Sciences's current Cyclically Adjusted Book per Share is €2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Wave Life Sciences (HAM:0VS) has a current Cyclically Adjusted Book per Share of €2.32. The stock's GF Value™ is €3.90, compared to a current price of €4.96 — trading 27.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is €2.32. Wave Life Sciences' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Wave Life Sciences (HAM:0VS), the current Cyclically Adjusted Book per Share is €2.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wave Life Sciences (HAM:0VS) Overvalued in 2026?

Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued. The current stock price of €4.96 is trading 27.2% above its estimated GF Value™ of €3.90.

Key valuation signals for HAM:0VS:

  • Cyclically Adjusted Book per Share: €2.32
  • GF Value™: €3.90 vs. price of €4.96 (27.2% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the HAM:0VS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wave Life Sciences Business Description

Other Exchanges WVE:USA1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
58GF Score

Get the complete analysis for HAM:0VS

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.96
Price
€3.90
GF Value